20
Participants
Start Date
April 18, 2024
Primary Completion Date
March 31, 2028
Study Completion Date
March 31, 2028
Infliximab
"Infliximab has FDA approval for the treatment of rheumatoid arthritis and inflammatory bowel syndrome. The current proposal represents the use of infliximab as an experimental tool to dissect the role of inflammatory processes leading to changes in brain reward circuitry and changes in specific symptom domains.~Double-blinded infusions of infliximab will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist."
Placebo
Double-blinded infusions of saline will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist.
NOT_YET_RECRUITING
Grady Memorial Hospital, Atlanta
RECRUITING
Emory University Hospital, Atlanta
National Institute of Mental Health (NIMH)
NIH
Emory University
OTHER